Emodin Suppresses NLRP3/GSDMD-induced Inflammation via the TLR4/MyD88/NF-κB Signaling Pathway in Atherosclerosis
- PMID: 39715879
- DOI: 10.1007/s10557-024-07659-w
Emodin Suppresses NLRP3/GSDMD-induced Inflammation via the TLR4/MyD88/NF-κB Signaling Pathway in Atherosclerosis
Abstract
Purpose: Inflammatory responses induced by NLRP3 inflammasome contribute to the progression of atherosclerosis. This study seeks to investigate the effect of emodin on the NLRP3 inflammasome in atherogenesis and to probe the underlying mechanism.
Methods: ApoE-knockout (ApoE-/-) mice were treated with a high-fat diet (HFD) for 12 weeks and intragastrically with emodin for 6 weeks. Human mononuclear cell line THP-1 was pretreated with emodin or signaling pathway inhibitors and induced into macrophages using phorbol 12-myristate 13-acetate (PMA) for 48 h. The NLRP3-mediated inflammatory response was studied both in vivo and in vitro. The level of the inflammation was detected by western blot, real-time PCR analysis, and ELISA.
Results: Emodin attenuated atherosclerotic lesions in HFD-treated ApoE-/- mice. Emodin dramatically decreased the expression of NLRP3, GSDMD, IL-1β, and IL-18 in HFD-treated ApoE-/- mice and PMA-induced macrophages. Moreover, emodin significantly hindered the activation of nuclear factor kappa-B (NF-κB) by inhibiting the formation of the TLR4/MyD88 complex in PMA-induced macrophages.
Conclusion: Our data demonstrate that emodin can inhibit the development of atherosclerotic plaques by alleviating NLRP3/GSDMD-induced inflammation through repressing the TLR4/MyD88/NF-κB signaling pathway in macrophages. This finding suggests that emodin can be a potential candidate for the treatment of atherosclerosis.
Keywords: Atherosclerosis; Emodin; GSDMD; NF-κB; NLRP3 inflammasome.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Ethics Approval: All of the experimental protocols received approval from the Laboratory Animal Ethics Committee, and the Laboratory Animal Centre of the First Affiliated Hospital of Wenzhou Medical University (WYYY-IACUC-AEC-2024–055) approved this study. Consent to Participate: Not applicable. Consent for Publication: Not applicable. Conflicts of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors report no conflict of interest in this work.
References
-
- Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–74. https://doi.org/10.1038/nature01323 . - DOI - PubMed
-
- Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362(6423):801–9. https://doi.org/10.1038/362801a0 . - DOI - PubMed
-
- Lamkanfi M, Kanneganti TD. Nlrp3: an immune sensor of cellular stress and infection. Int J Biochem Cell Biol. 2010;42(6):792–5. https://doi.org/10.1016/j.biocel.2010.01.008 . - DOI - PubMed - PMC
-
- De Nardo D, Latz E. NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol. 2011;32(8):373–9. https://doi.org/10.1016/j.it.2011.05.004 . - DOI - PubMed - PMC
-
- Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140(6):821–32. https://doi.org/10.1016/j.cell.2010.01.040 . - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
